This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 35Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2056 | Putrescine, spermidine, spermine, N-acetylspermine and N-acetylspermidine | Metabolite | Human | Upregulated in the plasma of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2057 | Spermine, followed by N-acetylspermidine, putrescine, cadaverine, spermidine, N-acetylspermine and N-acetylputrescine | Metabolite | Human | Upregulated in the urine of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2060 | Uracil | Metabolite | Mice | Downregulated | Potential Predictive * | Cancer v/s Normal; Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2061 | cis-Aconitate acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2062 | D-4-Phosphopantothenate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2063 | Progesterone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2064 | 5-Thymidylic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2065 | 2-Phospho-d-glyceric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2066 | Niacinamide | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2067 | Cortisone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2068 | Imidazoleacetic acid ribotide | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2069 | 3-Methyl-2-oxovaleric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2070 | Pseudoephedrine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2071 | 4-Phosphopantothenoylcysteine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2072 | Pantetheine 4-phosphate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2073 | Hippuric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2074 | 3-Hydroxyanthranilic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2075 | Glycine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2076 | Creatine | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2077 | Cortisol | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2078 | Allantoic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2079 | Pantothenic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2080 | Creatinine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2081 | Urea | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2082 | 5-Hydroxyindoleacetic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2083 | Phytosphingosine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2084 | Imidazoleacetic acid riboside | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.01 | Urine and Plasma | 27077962 |
2113 | Alpha-ketoglutaric | Metabolite | Human | The concentrations of α-KG in diabetic II and liver cancer urine samples were significantly lower than those from healthy people. | Diagnostic | Normal vs cancer | p < 0.05 | Urine | 25871588 |
2114 | pyruvic acid | Metabolite | Human | The concentrations of PA in diabetic II and liver cancer urine samples were significantly lower than those from healthy people. | Diagnostic | Normal vs cancer | p < 0.05 | Urine | 25871588 |
2120 | D-glucurono-6,3-lactone | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
2121 | glycerol-3-phosphate | Metabolite | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
2122 | pyruvic acid | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
2123 | lithocholic acid | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
2124 | 2-pyrocatechuic acid | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
2125 | prostaglandin E1 | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 |